Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
NeuroOne's earnings report highlights strong financial performance with record product sales and gross margins, along with a significant partnership expansion with Zimmer Biomet. Despite some uncertainties in the Q&A, the company's improved financial health, no debt, and guidance of being fully funded through fiscal 2026 are positive indicators. The competitive pressures and supply chain challenges are present but are outweighed by the strategic partnership and financial improvements. The stock is likely to see a positive reaction over the next two weeks.
Product Revenue (Q2 FY25) $1,400,000, unchanged year-over-year from Q2 FY24. Revenue expected to ramp through the end of the fiscal year as the product launch expands.
Product Revenue (First Half FY25) $4,700,000, an increase of 97% compared to $2,400,000 in the first half of FY24.
License Revenue (First Half FY25) $3,000,000, compared to $0 in the first half of FY24, derived from the expanded exclusive distribution agreement with Zimmer.
Product Gross Profit (Q2 FY25) $800,000 or 55.6% of revenue, compared to $400,000 or 28.3% of revenue in Q2 FY24.
Product Gross Profit (First Half FY25) $2,700,000 or 57.9% of revenue, compared to $700,000 or 27.9% of revenue in the first half of FY24.
Total Operating Expenses (Q2 FY25) $3,500,000, compared to $3,300,000 in Q2 FY24.
R&D Expense (Q2 FY25) $1,500,000, compared to $1,300,000 in Q2 FY24.
SG&A Expense (Q2 FY25) $1,900,000, decreased from $2,000,000 in Q2 FY24.
Total Operating Expenses (First Half FY25) $6,700,000, a decrease of 4% compared to $6,900,000 in the first half of FY24.
R&D Expense (First Half FY25) $2,700,000, a decrease of 3% compared to $2,800,000 in the first half of FY24.
SG&A Expense (First Half FY25) $4,000,000, a decrease of 5% compared to $4,200,000 in the first half of FY24.
Net Loss (Q2 FY25) $2,300,000 or $0.07 per share, improved from a net loss of $2,900,000 or $0.11 per share in Q2 FY24.
Net Loss (First Half FY25) $500,000 or $0.02 per share, improved significantly from a net loss of $6,200,000 or $0.25 per share in the first half of FY24.
Cash and Cash Equivalents (as of March 31, 2025) $1,300,000, compared to $1,400,000 as of September 30, 2024.
Working Capital (as of March 31, 2025) $2,000,000, compared to $2,400,000 as of September 30, 2024.
Net Cash from Financing $8,200,000 in net proceeds from a capital raise, which is expected to fully fund the company through at least fiscal year 2026.
Product Revenue: Product revenue increased 97% to $4,700,000 in the first half of fiscal 2025.
1RF Ablation System: The 1RF ablation system is FDA cleared and commercially available, treating patients with epilepsy.
Trigeminal Nerve Ablation System: Filed a 510 submission with the FDA for the 1RF trigeminal nerve ablation system to treat facial pain.
Market Expansion: Initiating ISO 13485 certification process to commercialize products internationally.
Strategic Partnership: Exclusive distribution rights with Zimmer Biomet for the 1RF ablation system.
Operational Efficiency: Product gross margins increased to 57.9%, more than double from the previous year.
Cost Reduction: Bringing critical functions in-house with new hires to reduce costs.
Strategic Growth Initiatives: Focused on ramping revenues and expanding product margins.
Cash Flow Breakeven: Anticipate reaching cash flow breakeven if key milestones are achieved.
Regulatory Risks: The company is pursuing FDA clearance for its 1RF trigeminal nerve ablation system, which is critical for expanding its product offerings. Delays or rejections in the regulatory process could impact revenue generation.
Competitive Pressures: NeuroOne faces competition from other medical technology companies offering similar solutions. The need to maintain a competitive edge through innovation and effective marketing is essential.
Supply Chain Challenges: The company relies on strategic distribution partners like Zimmer Biomet. Any disruptions in these partnerships or supply chain issues could affect product availability and revenue.
Economic Factors: Economic downturns or changes in healthcare funding could impact hospital budgets and the adoption of new medical technologies, potentially affecting sales.
Market Adoption: Achieving mass adoption of the 1RF ablation system is crucial. The company must ensure that targeted hospitals continue to use their technology to treat eligible patients.
International Expansion Risks: The company is initiating efforts to secure ISO 13485 certification for international markets. The lack of prior experience in these markets poses risks in terms of regulatory compliance and market entry.
Product Revenue Growth: Product revenue increased 97% to $4,700,000 in the first half of fiscal 2025.
Product Gross Margin: Product gross margins increased to 57.9%, more than double the previous year.
FDA Submission: Filed a 510 submission with the FDA for the 1RF trigeminal nerve ablation system, expected to generate revenues by late calendar year 2025.
Strategic Partnerships: In discussions with top-tier strategic partners for applications in spinal cord nerve ablation and spinal cord stimulation.
International Expansion: Initiating ISO 13485 certification process to commercialize products internationally.
Leadership Additions: Welcomed Dr. Parag Patel as Chief Medical Advisor to enhance clinical expertise.
Fiscal Year 2025 Revenue Guidance: Expect product revenue to be in the range of $8,000,000 to $10,000,000, representing an increase of 132-190% over fiscal 2024.
Product Gross Margin Guidance: Expected product gross margin to be between 47% and 51% for fiscal 2025.
Funding Outlook: Anticipate being fully funded through at least fiscal year 2026, with potential to reach cash flow breakeven.
License Revenue: $3,000,000 received from Zimmer in the first six months of fiscal twenty twenty five.
Capital Raise: $8,200,000 in net proceeds from a successful capital raise with institutional investors.
Cash on Hand: $9,400,000 as of April, including financing.
No Debt: The company has no debt outstanding as of March 31, 2025.
Funding Guidance: The company believes it is fully funded through at least fiscal year twenty twenty six.
The earnings call reveals strong financial performance with significant improvements in gross margins and a reduced net loss. The strategic plan outlines ambitious growth prospects, including new product developments and market expansions. Although some uncertainty exists around partnerships and timelines, the overall sentiment is optimistic with increased revenue guidance and improved financial health. The Q&A section did not highlight any major concerns, supporting a positive outlook. Given these factors, a positive stock price movement is likely over the next two weeks.
The earnings call reveals strong financial performance, with significant revenue and margin growth, reduced expenses, and improved net loss. The partnership with Zimmer Biomet and international expansion plans are promising. Despite management's cautious stance on 2026 guidance, the optimistic FY 2025 outlook and strategic partnerships suggest a strong positive sentiment. The Q&A session highlights potential growth areas and addresses concerns, further solidifying the positive outlook. Given the context and potential for expansion, a strong positive stock price movement is expected, likely exceeding 8%.
The earnings call highlights strong financial performance, including record revenue and gross margins, a significant partnership with Zimmer Biomet, and improved net loss figures. The Q&A reveals reliance on Zimmer for revenue and some uncertainty regarding non-Zimmer revenue, but overall sentiment remains positive due to the partnership's potential and no debt. The capital raise ensures financial stability, and the addition of a Chief Medical Advisor indicates strategic growth. Despite some risks and uncertainties, the overall outlook is positive, likely resulting in a stock price increase of 2% to 8%.
NeuroOne's earnings report highlights strong financial performance with record product sales and gross margins, along with a significant partnership expansion with Zimmer Biomet. Despite some uncertainties in the Q&A, the company's improved financial health, no debt, and guidance of being fully funded through fiscal 2026 are positive indicators. The competitive pressures and supply chain challenges are present but are outweighed by the strategic partnership and financial improvements. The stock is likely to see a positive reaction over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
